BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 14711314)

  • 21. Structure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist Zyklophin.
    Joshi AA; Murray TF; Aldrich JV
    J Med Chem; 2015 Nov; 58(22):8783-95. PubMed ID: 26491810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
    Zhang A; Xiong W; Bidlack JM; Hilbert JE; Knapp BI; Wentland MP; Neumeyer JL
    J Med Chem; 2004 Jan; 47(1):165-74. PubMed ID: 14695830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
    J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
    Dolle RE; Michaut M; Martinez-Teipel B; Seida PR; Ajello CW; Muller AL; DeHaven RN; Carroll PJ
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3647-50. PubMed ID: 19464172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
    Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors.
    Knapp RJ; Santoro G; De Leon IA; Lee KB; Edsall SA; Waite S; Malatynska E; Varga E; Calderon SN; Rice KC; Rothman RB; Porreca F; Roeske WR; Yamamura HI
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1284-91. PubMed ID: 8667189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. De novo design, synthesis, and pharmacology of alpha-melanocyte stimulating hormone analogues derived from somatostatin by a hybrid approach.
    Han G; Haskell-Luevano C; Kendall L; Bonner G; Hadley ME; Cone RD; Hruby VJ
    J Med Chem; 2004 Mar; 47(6):1514-26. PubMed ID: 14998337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and synthesis of 1-aminocycloalkane-1-carboxylic acid-substituted deltorphin analogues: unique delta and mu opioid activity in modified peptides.
    Breveglieri A; Guerrini R; Salvadori S; Bianchi C; Bryant SD; Attila M; Lazarus LH
    J Med Chem; 1996 Feb; 39(3):773-80. PubMed ID: 8576920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and biological properties of highly potent cyclic dynorphin A analogues. Analogues cyclized between positions 5 and 11.
    Meyer JP; Collins N; Lung FD; Davis P; Zalewska T; Porreca F; Yamamura HI; Hruby VJ
    J Med Chem; 1994 Nov; 37(23):3910-7. PubMed ID: 7966152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological and conformational examination of stereochemical modifications using the template melanotropin peptide, Ac-Nle-c[Asp-His-Phe-Arg-Trp-Ala-Lys]-NH2, on human melanocortin receptors.
    Haskell-Luevano C; Nikiforovich G; Sharma SD; Yang YK; Dickinson C; Hruby VJ; Gantz I
    J Med Chem; 1997 May; 40(11):1738-48. PubMed ID: 9171884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
    Katsura Y; Zhang X; Homma K; Rice KC; Calderon SN; Rothman RB; Yamamura HI; Davis P; Flippen-Anderson JL; Xu H; Becketts K; Foltz EJ; Porreca F
    J Med Chem; 1997 Aug; 40(18):2936-47. PubMed ID: 9288176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.
    Kawasaki AM; Knapp RJ; Kramer TH; Walton A; Wire WS; Hashimoto S; Yamamura HI; Porreca F; Burks TF; Hruby VJ
    J Med Chem; 1993 Mar; 36(6):750-7. PubMed ID: 8096246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent cyclic monomeric and dimeric peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion based on the Ile-Leu-Asp-Val tetrapeptide.
    Dutta AS; Crowther M; Gormley JJ; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Jamieson A; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
    J Pept Sci; 2000 Jul; 6(7):321-41. PubMed ID: 10946997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and pharmacological activities of dynorphin A analogues cyclized by ring-closing metathesis.
    Fang WJ; Cui Y; Murray TF; Aldrich JV
    J Med Chem; 2009 Sep; 52(18):5619-25. PubMed ID: 19715279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pro(3)]Dyn A(1-11)-NH(2): a dynorphin analogue with high selectivity for the kappa opioid receptor.
    Schlechtingen G; Zhang L; Maycock A; DeHaven RN; Daubert JD; Cassel J; Chung NN; Schiller PW; Goodman M
    J Med Chem; 2000 Jul; 43(14):2698-702. PubMed ID: 10893307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues.
    Orbuch M; Taylor JE; Coy DH; Mrozinski JE; Mantey SA; Battey JF; Moreau JP; Jensen RT
    Mol Pharmacol; 1993 Oct; 44(4):841-50. PubMed ID: 7901752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides.
    Rivier JE; Kirby DA; Erchegyi J; Waser B; Eltschinger V; Cescato R; Reubi JC
    J Med Chem; 2005 Jan; 48(2):515-22. PubMed ID: 15658865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-activity relationships of dynorphin analogs substituted in positions 2 and 3.
    Schlechtingen G; DeHaven RN; Daubert JD; Cassel J; Goodman M
    Biopolymers; 2003; 71(1):71-6. PubMed ID: 12712501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N,N-diallyl-tyrosyl substitution confers antagonist properties on the kappa-selective opioid peptide [D-Pro10]dynorphin A(1-11).
    Gairin JE; Mazarguil H; Alvinerie P; Botanch C; Cros J; Meunier JC
    Br J Pharmacol; 1988 Dec; 95(4):1023-30. PubMed ID: 2905908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.